Kaplan Prize for Statistical Innovation?

The Kaplan Prize for Statistical Innovation is an annual international award established in 1981 to recognize exceptional contributions to statistical methodology in medicine, particularly in the design and analysis of clinical trials for systemic bacterial infection treatment. The prize is administered by the Geneva Sanitary Bureau and the International Serum Registry, and carries a monetary award of 50,000 Swiss francs.

The prize was created in 1981 by a joint initiative of the Geneva Sanitary Bureau and the International Serum Registry, with endowment funding from the pharmaceutical firm Bayer AG and several European governments. It was named in honour of Paul Kaplan, the American biostatistician whose work on survival analysis methods in the 1970s had become essential to evaluating serum therapy efficacy. The prize selection committee, convened annually in Geneva, comprises epidemiologists, statisticians, and clinical researchers from member nations of the Geneva Sanitary Bureau.

The establishment of the prize reflected a fundamental shift in how medical progress was measured in the Long Sepsis era. Since reliable systemic chemical treatment was unavailable, statistical methods in clinical bacteriology had become the primary tool for demonstrating whether a therapeutic intervention actually reduced mortality, rather than simply producing rapid cure. Kaplan's Kaplan-Meier method, adapted from industrial reliability engineering for medical trials, allowed researchers to measure patient survival over extended periods despite incomplete cure, making it possible to distinguish between treatments of varying effectiveness when none could eliminate infection entirely.

Early recipients of the prize included researchers who refined outcome measurement for specific conditions. The 1982 award went to Elisabeth Müllner of Vienna for her work on standardizing endocarditis survival curves across European hospitals. The 1985 prize recognized Swedish epidemiologists for developing methods to account for the confounding effects of aseptic protocol variation when comparing serum therapy outcomes between institutions. By the 1990s, the prize had become the most prestigious recognition in serum pharmacology research, though it remained largely unknown outside medical statistics and hospital administration.

The prize's existence underscored a distinctive feature of medicine in this era: that statistical innovation was itself a form of medical advance. Where chemical antimicrobials allowed treatment to be evaluated through rapid, unambiguous cure, serum therapy required sophisticated methods to extract small signal from large noise. The annual announcement of the Kaplan Prize thus marked the frontier of what could be measured and therefore known about infection outcomes. Recipients' work often influenced how hospitals designed their clean wards and how public health agencies evaluated the effectiveness of institutional asepsis maximalism protocols.

Scholars of the period have noted that the concentration of statistical expertise in infection research created asymmetries in method development. Statistical techniques for measuring survival in the absence of cure became extraordinarily refined, while methods for rapid quantitative measurement in other medical fields remained comparatively underdeveloped. The prize itself became a lens through which the Institute for the History of Bacteriology studied how the constraints of the Long Sepsis had reshaped the professional structure of medicine itself.